Evidence-based·Last reviewed May 31, 2026·How we grade evidence

Bifidobacterium (mixed)

Q: Why combine multiple Bifidobacterium species?

Different species occupy different niches in the gut and may have complementary effects. Multi-strain formulas aim to broaden the microbiome support, though clinical evidence for combinations versus single strains is mixed.

Q: Is Bifidobacterium better than Lactobacillus?

They serve different roles. Bifidobacterium is more abundant in the colon and ferments fibers, while Lactobacillus dominates the small intestine and produces lactic acid. Many products combine both for broader effects.

Q: How long until I see results?

For chronic conditions like IBS, allow 2 to 4 weeks of consistent use to evaluate effects. Some users notice subtle improvements sooner.

Q: Should I take Bifidobacterium with prebiotic fiber?

Yes. Prebiotic fibers (chicory inulin, FOS, galactooligosaccharides) feed Bifidobacterium and may enhance their effects. Many products combine probiotics with prebiotics as 'synbiotics.'

Q: Is Bifidobacterium safe for infants?

B. infantis is naturally dominant in the infant gut and is generally safe. Specific infant probiotic products are formulated for pediatric use. Consult a pediatrician for infant probiotic use, especially in premature infants.

ProbioticMixed diacylamineBest before bedBest taken with food

Multi-strain Bifidobacterium products have decent evidence for preventing antibiotic-associated diarrhea and reducing IBS symptoms when the SPECIFIC strain mix has been tested. But strain matters more than genus — 'a Bifidobacterium' isn't interchangeable with another. Most marketing claims on probiotic bottles outrun the evidence for that specific product.

Quick decision guide

May help most

Adults starting a course of antibiotics (especially in hospital or high-risk for C. difficile); adults with IBS willing to trial a tested multi-strain formula for 4–8 weeks.

Common dosing range

1–25 billion CFU/day (varies by product); higher doses generally tested for AAD prevention and IBS.

When to expect effects

Days during antibiotic courses; 4–8 weeks for IBS symptom response.

Watch out for

Avoid in severely immunocompromised, critically ill, or central-venous-catheter patients — case reports of probiotic-associated bacteremia and sepsis.

Evidence snapshot

Antibiotic-associated diarrhea preventionModerate

C. difficile-associated diarrhea preventionModerate

IBS symptom reliefEmerging

General gut/immune support in healthy adultsLow

What is it

Bifidobacterium is a genus of beneficial bacteria that are among the most abundant residents of the human gut, particularly in infants and the colon of healthy adults. Mixed Bifidobacterium probiotic formulas contain multiple species (such as B. bifidum, B. lactis, B. longum, and B. infantis) intended to broaden gut microbiome support.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You're starting antibiotics and want to reduce the risk of antibiotic-associated diarrhea — start within 2 days of antibiotic initiation

You're high-risk for C. difficile (hospital admission, broad-spectrum antibiotics, older age) and your physician suggests probiotic prophylaxis

You have IBS and want to trial a tested multi-strain formula for 4–8 weeks alongside dietary changes

You're recovering from a documented gut infection and want short-term microbiome support

Probably skip if…

You're severely immunocompromised, have a central venous catheter, are critically ill in ICU, or have damaged gut mucosa — case reports of bacteremia

You expect general 'gut and immune support' in a healthy adult — daily prophylactic probiotics in healthy people have not been shown to deliver clinical benefits

You're choosing a generic 'Bifido blend' with no published trials on the actual strain composition — strain specificity matters

You expect rapid (days-to-weeks) effects for IBS without dietary changes

Evidence at a glance

Goal	Effect	Best fit	Time
Antibiotic-associated diarrhea prevention Good Evidence	Roughly halves AAD incidence (RR ~0.45); NNT ≈ 9 in children, similar magnitude in adults	Children and adults receiving systemic antibiotics, especially broad-spectrum agents (clindamycin, fluoroquinolones, cephalosporins); start within 2 days	Effective during the antibiotic course; continue for 1 week after antibiotic finish
C. difficile-associated diarrhea (CDI) prevention Good Evidence	62% relative risk reduction; NNT ≈ 12 for high-risk hospitalized adults on antibiotics	Hospitalized adults receiving antibiotics, older patients, those with prior CDI episodes; coordinate with infectious disease or pharmacy	Throughout antibiotic course and 1–2 weeks after
Irritable bowel syndrome (IBS) symptom relief Limited Evidence	Modest (~20% greater symptom reduction vs placebo) in trial-tested strains; minimal evidence for generic multi-strain blends without trials	Adults with diagnosed IBS willing to trial a specific trial-tested product for 4–8 weeks alongside dietary modification	4–8 weeks for symptom plateau in trials
General 'immune' and 'gut health' support in healthy adults Mixed Evidence	No reliable clinical-endpoint benefit in healthy adults	(None — healthy adults don't need daily probiotics)	Not established
Restoring microbiome after gut infection Mixed Evidence	Unclear in adults; modest diarrhea-duration reduction in children with non-Bifido strains	Adults with prolonged post-infectious bowel changes who try a tested product for 4 weeks	Days for acute diarrhea; weeks for post-infectious symptoms

Antibiotic-associated diarrhea prevention

Good Evidence

Effect: Roughly halves AAD incidence (RR ~0.45); NNT ≈ 9 in children, similar magnitude in adults
Best fit: Children and adults receiving systemic antibiotics, especially broad-spectrum agents (clindamycin, fluoroquinolones, cephalosporins); start within 2 days
Time: Effective during the antibiotic course; continue for 1 week after antibiotic finish

C. difficile-associated diarrhea (CDI) prevention

Good Evidence

Effect: 62% relative risk reduction; NNT ≈ 12 for high-risk hospitalized adults on antibiotics
Best fit: Hospitalized adults receiving antibiotics, older patients, those with prior CDI episodes; coordinate with infectious disease or pharmacy
Time: Throughout antibiotic course and 1–2 weeks after

Irritable bowel syndrome (IBS) symptom relief

Limited Evidence

Effect: Modest (~20% greater symptom reduction vs placebo) in trial-tested strains; minimal evidence for generic multi-strain blends without trials
Best fit: Adults with diagnosed IBS willing to trial a specific trial-tested product for 4–8 weeks alongside dietary modification
Time: 4–8 weeks for symptom plateau in trials

General 'immune' and 'gut health' support in healthy adults

Mixed Evidence

Effect: No reliable clinical-endpoint benefit in healthy adults
Best fit: (None — healthy adults don't need daily probiotics)
Time: Not established

Restoring microbiome after gut infection

Mixed Evidence

Effect: Unclear in adults; modest diarrhea-duration reduction in children with non-Bifido strains
Best fit: Adults with prolonged post-infectious bowel changes who try a tested product for 4 weeks
Time: Days for acute diarrhea; weeks for post-infectious symptoms

Evidence for 5 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Antibiotic-associated diarrhea prevention

Supplement benefit

Good Evidence

The Guo et al. 2019 Cochrane review of 33 pediatric AAD trials (6,352 children) found probiotics reduced AAD from 19% to 8% (RR 0.45, 95% CI 0.36–0.56, NNT 9), with moderate-certainty evidence at higher doses (≥5 billion CFU/day). The strongest individual strain evidence is for L. rhamnosus GG and S. boulardii; mixed-Bifido products are commonly used but the evidence for the specific multi-strain product depends on its individual trial record. Start within 2 days of antibiotic initiation for best effect.

Effect size

Roughly halves AAD incidence (RR ~0.45); NNT ≈ 9 in children, similar magnitude in adults

Time to effect

Effective during the antibiotic course; continue for 1 week after antibiotic finish

Best fit

Children and adults receiving systemic antibiotics, especially broad-spectrum agents (clindamycin, fluoroquinolones, cephalosporins); start within 2 days

Less likely

Patients on narrow-spectrum oral antibiotics for short courses (e.g., 3-day nitrofurantoin for cystitis) — baseline AAD risk is low

Bottom line: Probiotics started early in an antibiotic course meaningfully reduce diarrhea. Best evidence is for specific tested strains/products; check the bottle's clinical research backing.

SourceGuo et al., 2019 — Cochrane probiotics for pediatric AAD — Cochrane Database of Systematic Reviews Goldenberg et al., 2017 — Cochrane probiotics for CDI — Cochrane Database of Systematic Reviews

C. difficile-associated diarrhea (CDI) prevention

Supplement benefit

Good Evidence

The Goldenberg 2017 Cochrane review of 31 trials (8,672 adults and children) found probiotics reduced CDI from 4.0% to 1.5% (NNT ≈ 12 for high-risk patients), with moderate-certainty evidence. Effect was most consistent in patients with baseline CDI risk >5%. Mixed-strain products containing Lactobacillus + Bifidobacterium species were the most-tested formulations. This is an in-hospital / high-risk-outpatient intervention, not a general wellness measure.

Effect size

62% relative risk reduction; NNT ≈ 12 for high-risk hospitalized adults on antibiotics

Time to effect

Throughout antibiotic course and 1–2 weeks after

Best fit

Hospitalized adults receiving antibiotics, older patients, those with prior CDI episodes; coordinate with infectious disease or pharmacy

Less likely

Healthy outpatients on short antibiotic courses with low baseline CDI risk

Bottom line: A reasonable adjunct in high-risk antibiotic recipients — discuss with the prescribing clinician for hospital settings. Not a substitute for antibiotic stewardship.

SourceGoldenberg et al., 2017 — Cochrane probiotics for CDI — Cochrane Database of Systematic Reviews

Irritable bowel syndrome (IBS) symptom relief

Supplement benefit

Limited Evidence

Strain-specific evidence is real but variable. The Whorwell 2006 trial (PMID 16863564) of 362 IBS patients found B. infantis 35624 at 1×10^8 CFU/day reduced abdominal pain, bloating, bowel dysfunction, and incomplete evacuation more than placebo, with global symptom improvement >20% above placebo (p<0.02). Multi-strain Bifido + Lacto products (e.g., the Skrzydło-Radomańska 2021 trial) showed similar IBS-D symptom benefit. Effect is modest and depends on the specific formulation — generic 'Bifido' supplements without published trial data are unlikely to match the trial-tested products.

Effect size

Modest (~20% greater symptom reduction vs placebo) in trial-tested strains; minimal evidence for generic multi-strain blends without trials

Time to effect

4–8 weeks for symptom plateau in trials

Best fit

Adults with diagnosed IBS willing to trial a specific trial-tested product for 4–8 weeks alongside dietary modification

Less likely

People with non-specific bloating, generic GI discomfort, or undiagnosed symptoms — work up the diagnosis first

Bottom line: Worth a 4–8 week trial of a specifically tested product. Don't expect generic 'Bifido' blends to match the trial-validated formulas.

Evidence is mixed

Heterogeneity across trials is substantial. Many supplements list multiple Bifido strains without naming the specific deposit/identifier (e.g., 'B. infantis' vs 'B. infantis 35624'). Strain-level identity matters for benefit reproducibility.

SourceWhorwell et al., 2006 — B. infantis 35624 in IBS — PubMed — Am J Gastroenterol· conflicting Skrzydło-Radomańska et al., 2021 — Multi-strain probiotic (incl. Bifido) in IBS-D — PMC — J Clin Med· conflicting

SourceWhorwell et al., 2006 — B. infantis 35624 in IBS — PubMed — Am J Gastroenterol Skrzydło-Radomańska et al., 2021 — Multi-strain probiotic (incl. Bifido) in IBS-D — PMC — J Clin Med

General 'immune' and 'gut health' support in healthy adults

Mixed Evidence

Routine daily probiotic use in healthy adults has not been shown to reduce illness frequency, severity, or duration in well-conducted trials. The World Gastroenterology Organisation guidelines explicitly note that benefits are strain- and indication-specific, and don't recommend routine probiotic use in healthy people. The microbiome's resilience means most probiotic strains don't persist in the gut after stopping — measurable colonization is short-lived.

Effect size

No reliable clinical-endpoint benefit in healthy adults

Time to effect

Not established

Best fit

(None — healthy adults don't need daily probiotics)

Less likely

Anyone hoping a daily probiotic will deliver measurable wellness gains without a specific indication

Bottom line: If you're healthy and not on antibiotics, eat fermented foods and fiber. Don't pay for daily probiotics for general wellness.

SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

Restoring microbiome after gut infection

Mechanism only

Mixed Evidence

Mechanistically appealing, but trial data are limited. Recovery from acute gastroenteritis is usually self-limited in adults. Probiotic shortening of acute diarrhea is best supported for S. boulardii and L. rhamnosus GG in children. For adults post-infection, the case for mixed-Bifido products is mostly extrapolation.

Effect size

Unclear in adults; modest diarrhea-duration reduction in children with non-Bifido strains

Time to effect

Days for acute diarrhea; weeks for post-infectious symptoms

Best fit

Adults with prolonged post-infectious bowel changes who try a tested product for 4 weeks

Less likely

Acute self-limited gastroenteritis with no ongoing symptoms

Bottom line: Reasonable to try short-term after a documented infection; don't expect dramatic long-term microbiome 'reset.'

SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

How it works

Bifidobacterium species ferment dietary fibers and oligosaccharides in the colon to produce short-chain fatty acids (SCFAs), particularly acetate, which support colonocyte energy metabolism, gut barrier integrity, and immune regulation. They produce antimicrobial compounds, compete with pathogens for binding sites, and influence the broader gut microbial community through cross-feeding interactions. Different Bifidobacterium species occupy distinct niches and have somewhat different effects. B. infantis dominates the infant gut and metabolizes human milk oligosaccharides. B. longum and B. lactis are common in adults and have specific strains with evidence for IBS, immune function, and gut health. Mixed formulas aim to provide a broader microbial spectrum, though specific strain choices and clinical evidence vary by product. Bifidobacterium counts in the gut tend to decline with age, antibiotic use, and certain disease states. Probiotic supplementation may transiently raise their numbers and exert effects during transit, but most strains do not permanently colonize. Consistent intake is needed to maintain effects.

How to take it

1. Typical dose

• AAD/CDI prevention: 5–25 billion CFU/day, started within 2 days of antibiotic initiation • IBS: dose-per-trial of the specific product chosen (typically 1–10 billion CFU/day) • General: not recommended for daily use in healthy adults without indication

2. Higher studied dose

Up to 50–100 billion CFU/day has been used in some hospital CDI-prevention trials without safety signal in immunocompetent patients. Higher doses are not necessarily more effective.

3. Timing

Take with food, 2 hours apart from each antibiotic dose to give live bacteria time to establish without being killed. Refrigerated products: keep cold; shelf-stable products are formulated for room temperature.

4. With food

With food.

5. Split dosing

Daily probiotic dose can usually be a single morning capsule. For multi-billion CFU products, split dosing into morning and evening may improve gut transit timing — check the manufacturer's instructions.

6. How long to try

Throughout the antibiotic course plus 1–2 weeks after for AAD prevention. 4–8 weeks for IBS to judge response. Long-term continuous use (months-years) lacks evidence and isn't generally recommended.

What to track

Diarrhea frequency during antibiotic course

IBS symptom diary at baseline, 4 weeks, 8 weeks

Bloating or initial gas (often peaks in week 1–2, then subsides)

Stool form (Bristol scale) for IBS-D or IBS-C

Any fever or systemic symptoms — should prompt immediate medical evaluation

Bottom line: Start the right product for the right indication, at the right time. For antibiotics, start within 2 days. For IBS, commit to a 4–8 week trial of a specifically-studied formula.

5 commercial forms

Compare the main delivery options and what they’re best suited for.

Multi-strain capsule (Lactobacillus + Bifidobacterium)

Most-studied AAD format

Standard format for most clinical-grade probiotic trials. CFU dose per capsule varies widely (1–50 billion). Look for products with published trials on the exact formulation, not extrapolation from single-strain studies.

Enteric coating or acid-resistant capsule improves gut delivery.

Single-strain Bifidobacterium product (e.g., B. infantis 35624)

Strain-specific IBS evidence

The form used in the strongest IBS trials. Reproducible because the strain is identified to deposit number. Sometimes cheaper than mega-blend products and easier to match to a specific evidence base.

Single-strain dose typically 1×10^8–1×10^9 CFU/day.

Multi-strain powder (sachet)

Higher CFU, mixing into food/drink

Often used for high-dose hospital CDI prevention protocols (50–450 billion CFU). Mix into cold liquid or applesauce. Don't add to hot drinks — heat kills live bacteria.

Convenient for high doses and pediatric/elderly populations.

Fermented foods (yogurt, kefir, kimchi, sauerkraut, kombucha)

Natural source

CFU content is unpredictable but real. Strain composition varies by brand and batch. Provides additional benefits beyond live bacteria (lactic-acid metabolites, vitamins from fermentation). Reasonable as a daily food-based source.

Variable CFU; not a substitute for specific clinical-grade products when an indication exists.

Spore-based probiotics (Bacillus species)

Different class

Not Bifidobacterium — included here for comparison. Bacillus spores survive stomach acid better and don't need refrigeration. Different evidence base; not interchangeable with Bifido products for AAD, CDI, or IBS.

Highly stable; different clinical evidence profile.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

initial gas, bloating, mild constipation (typically resolves in 1–2 weeks)bowel-habit changes

Serious risks

Probiotic-associated bacteremia and sepsis have been reported in severely immunocompromised patients, those with central venous catheters, critically ill ICU patients, or those with damaged gut mucosa (severe pancreatitis, neutropenia). Avoid in these settings without specialist input.
SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO
PROPATRIA trial (2008) found probiotic prophylaxis in severe acute pancreatitis was associated with increased mortality — probiotics are contraindicated in this setting.
SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

Who should avoid it

Severely immunocompromised patients (active hematologic malignancy, transplant recipients on heavy immunosuppression, severe neutropenia) — bacteremia risk.
SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO
Patients with central venous catheters or implanted medical devices — translocation risk.
SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO
Critically ill ICU patients or those with severe pancreatitis — increased mortality signal.
SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO
Premature infants without neonatal-specialist supervision — strain choice and dose matter; some strains have been linked to sepsis case reports.
SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

Pregnancy & breastfeeding

Lactobacillus and Bifidobacterium strains taken orally are generally considered safe in pregnancy and lactation. They are naturally present in the maternal microbiome and breast milk. No major safety signals in pregnancy at typical supplemental doses. Discuss with your obstetrician if you have any pregnancy complication that puts you at higher infection risk.

SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

Bottom line: Very safe for the general population. The serious risks are concentrated in specific clinical scenarios — immunosuppression, catheters, ICU, severe pancreatitis — where they're contraindicated.

Interactions

immunosuppressants (tacrolimus, cyclosporine, biologics)Moderate

Theoretical translocation/bacteremia risk in heavily immunosuppressed patients. Discuss with the prescribing specialist before starting probiotics on these drugs.

SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

chemotherapy with neutropeniaModerate

Avoid live probiotic supplements when neutrophil count is severely low — bacteremia risk. Resume only with oncology approval.

SourceWorld Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO

antibiotics (oral)Minor

Antibiotics can kill live bacteria in probiotic products. Separate doses by at least 2 hours to give the probiotic time to establish before the next antibiotic dose. The interaction is mostly about preserving probiotic viability, not a drug-level interaction.

SourceGuo et al., 2019 — Cochrane probiotics for pediatric AAD — Cochrane Database of Systematic Reviews

Food sources

Food	Amount	%DV
Yogurt with live active cultures	1 cup (10^7–10^9 CFU)	—
Kefir	1 cup (10^7–10^10 CFU)	—
Aged cheeses (cheddar, gouda, Swiss)	1 oz (variable)	—
Sauerkraut, raw, unpasteurized	½ cup (10^6–10^8 CFU)	—
Kimchi	½ cup (10^6–10^8 CFU)	—
Miso paste	1 tbsp (variable)	—
Kombucha	1 cup (variable)	—
Tempeh	½ cup (variable, low after cooking)	—

Yogurt with live active cultures

Amount: 1 cup (10^7–10^9 CFU)
%DV: —

Kefir

Amount: 1 cup (10^7–10^10 CFU)
%DV: —

Aged cheeses (cheddar, gouda, Swiss)

Amount: 1 oz (variable)
%DV: —

Sauerkraut, raw, unpasteurized

Amount: ½ cup (10^6–10^8 CFU)
%DV: —

Kimchi

Amount: ½ cup (10^6–10^8 CFU)
%DV: —

Miso paste

Amount: 1 tbsp (variable)
%DV: —

Kombucha

Amount: 1 cup (variable)
%DV: —

Tempeh

Amount: ½ cup (variable, low after cooking)
%DV: —

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Strain identity stated to deposit-number level (e.g., 'Bifidobacterium longum BB536' or 'B. infantis 35624') — not just genus and species

CFU count guaranteed THROUGH EXPIRATION, not 'at time of manufacture' (which lets potency drop substantially by purchase time)

Refrigerated or proven shelf-stable storage requirement clearly stated

Multi-strain formulas with PUBLISHED clinical trials on the EXACT formulation (some products cite trials on different strain combinations)

Third-party tested (USP, NSF, ConsumerLab) for CFU count, identity, and contaminant absence

Be skeptical of…

Vague 'gut and immune support' claims on daily-use products for healthy adults — no clinical-endpoint evidence

'100 billion CFU' mega-dose marketing — more is not necessarily better; many positive trials used 1–10 billion CFU

Probiotics that don't name the specific strain (just 'Bifidobacterium blend') — strain identity is essential for benefit reproducibility

Cure-all claims (mood, weight loss, skin, anti-aging) — most psychobiotic and metabolic-probiotic data are early-stage and don't yet support consumer claims

Combination products mixing probiotics with high-dose fiber + digestive enzymes + herbs without clinical evidence for the combination

Frequently asked questions

Why combine multiple Bifidobacterium species?⌄

Different species occupy different niches in the gut and may have complementary effects. Multi-strain formulas aim to broaden the microbiome support, though clinical evidence for combinations versus single strains is mixed.

Is Bifidobacterium better than Lactobacillus?⌄

They serve different roles. Bifidobacterium is more abundant in the colon and ferments fibers, while Lactobacillus dominates the small intestine and produces lactic acid. Many products combine both for broader effects.

How long until I see results?⌄

For chronic conditions like IBS, allow 2 to 4 weeks of consistent use to evaluate effects. Some users notice subtle improvements sooner.

Should I take Bifidobacterium with prebiotic fiber?⌄

Yes. Prebiotic fibers (chicory inulin, FOS, galactooligosaccharides) feed Bifidobacterium and may enhance their effects. Many products combine probiotics with prebiotics as 'synbiotics.'

Is Bifidobacterium safe for infants?⌄

B. infantis is naturally dominant in the infant gut and is generally safe. Specific infant probiotic products are formulated for pediatric use. Consult a pediatrician for infant probiotic use, especially in premature infants.

References by claim

Antibiotic-associated diarrhea prevention

Goldenberg et al., 2017 — Cochrane probiotics for CDI — Cochrane Database of Systematic Reviews (2017) link

Guo et al., 2019 — Cochrane probiotics for pediatric AAD — Cochrane Database of Systematic Reviews (2019) link

Irritable bowel syndrome (IBS) symptom relief

Whorwell et al., 2006 — B. infantis 35624 in IBS — PubMed — Am J Gastroenterol (2006) link

Skrzydło-Radomańska et al., 2021 — Multi-strain probiotic (incl. Bifido) in IBS-D — PMC — J Clin Med (2021) link

General 'immune' and 'gut health' support in healthy adults

World Gastroenterology Organisation — Global Guidelines: Probiotics and Prebiotics — WGO (2023) link

Track Bifidobacterium (mixed) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store

Evidence-based·Last reviewed May 31, 2026·Evidence current as of May 31, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.